Reneo Pharmaceuticals, Inc. is a high-risk pharmaceutical company based in the United States of America. Specializing in developing therapies for rare genetic mitochondrial diseases, Reneo Pharmaceuticals, Inc. focuses on modulating genes critical to metabolism and ATP production. The company is working on REN001, a potential treatment to address the energy production issues associated with these diseases. With an ESG score of 35.7, Reneo Pharmaceuticals, Inc. is committed to environmental sustainability and governance practices.